Centogene AG already has revenues from patient use of its expansive genetic testing portfolio for orphan disease patients – as well as from biopharma partnerships including a deal with rare disease specialist Shire plc. Now, the Rostock, Germany-based start up has secured a €25 million (US$28 million) series A round to expand its presence globally, broaden its biomarker as well as companion and genetic diagnostic offerings, as well as to move into oncogenetics.